Abstract: The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.

Abstract: The present invention describes novel boron containing pyrazole compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described are methods of treating inflammation, auto-immune diseases, cancer, and other conditions that are susceptible to the inhibition of a Janus kinase by administering a compound herein described.

Abstract: The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.

Abstract: The present invention relates to solid forms of a substituted benzoxaborole compound, specifically crystalline forms of a compound of formula I, compositions comprising crystalline forms of the compound of formula (I), and methods of their use.

Abstract: A system for advanced metering includes a data concentration device and a data acquiring device. The data concentration device, configured to be physically attached to a first meter to obtain first data, includes a data interface capable of being electrically coupled to the first meter and a data concentration module capable of wireless communication using a first communication standard and wireless communication with a communication network using a second communication standard. The data acquiring device is configured to be physically attached to a second meter to obtain second data and capable of wireless communication using the first communication standard. The data concentration module transmits a first message including the first data to the communication network, selectively allows wireless communication using the first communication standard for the data acquiring device to enable transmission of the second data, and transmits a second message including the second data to the communication network.

Abstract: An operational amplifier includes a first output transistor and a second output transistor connected in series between two power nodes, the second output transistor having a semiconductor type opposite to the first output transistor, the first output transistor and the second output transistor being electrically coupled at an output node, and gates of the first output transistor and the second output transistor being connected to a first drive node and a second drive node respectively; and a decoupling capacitor circuit electrically connected between the first drive node and the second drive node.

Abstract: An operational amplifier includes a first output transistor and a second output transistor connected in series between two power nodes, the second output transistor having a semiconductor type opposite to the first output transistor, the first output transistor and the second output transistor being electrically coupled at an output node, and gates of the first output transistor and the second output transistor being connected to a first drive node and a second drive node respectively; and a decoupling capacitor circuit electrically connected between the first drive node and the second drive node.

Abstract: The present invention relates to solid forms of a substituted benzoxaborole compound, specifically crystalline forms of a compound of formula I, compositions comprising crystalline forms of the compound of formula (I), and methods of their use.

Abstract: The present invention relates to solid forms of a substituted benzoxaborole compound, specifically crystalline forms of a compound of formula I, compositions comprising crystalline forms of the compound of formula (I), and methods of their use.

Abstract: The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.

Abstract: A method is disclosed for altering the redox equilibrium of a transmembrane receptor-like protein tyrosine phosphatase (RPTP), particularly a type IIa RPTP, by chemically modulating the activity through contact of such an enzyme with a diaryl boron compound that preferentially reacts with an RPTP in an oxidized state (CyS-OH). This redox modulation is most readily observed and put to use by assaying the inhibition of the phosphatase activity of the RPTP. Such an assay can be carried out on an enzyme in vitro or by contacting the enzyme in a living organism (in vivo). A useful diaryl boron compound corresponds in structure to Formula I in which Ar-1, Ar-2, R1, R2, R3 and R4 are defined within. A pharmaceutical composition containing a useful diaryl boron compound is also disclosed, as are particularly preferred diaryl boron compounds.

Abstract: A system for advanced metering includes a data concentration device and a data acquiring device. The data concentration device, configured to be physically attached to a first meter to obtain first data, includes a data interface capable of being electrically coupled to the first meter and a data concentration module capable of wireless communication using a first communication standard and wireless communication with a communication network using a second communication standard. The data acquiring device is configured to be physically attached to a second meter to obtain second data and capable of wireless communication using the first communication standard. The data concentration module transmits a first message including the first data to the communication network, selectively allows wireless communication using the first communication standard for the data acquiring device to enable transmission of the second data, and transmits a second message including the second data to the communication network.

Abstract: A method is disclosed for altering the redox equilibrium of a transmembrane receptor-like protein tyrosine phosphatase (RPTP), particularly a type IIa RPTP, by chemically modulating the activity through contact of such an enzyme with a diaryl boron compound that preferentially reacts with an RPTP in an oxidized state (CyS-OH). This redox modulation is most readily observed and put to use by assaying the inhibition of the phosphatase activity of the RPTP. Such an assay can be carried out on an enzyme in vitro or by contacting the enzyme in a living organism (in vivo). A useful diaryl boron compound corresponds in structure to Formula I in which Ar-1, Ar-2, R1, R2, R3 and R4 are defined within. A pharmaceutical composition containing a useful diaryl boron compound is also disclosed, as are particularly preferred diaryl boron compounds.

Abstract: Benzoxaborole compounds and benzoxaborole compositions for increasing the growth of plants by inducing a growth enhancing effect within plants are described. Application of the compounds and/or composititons provides improved growth of treated plants, increases crop yield, improves quality, increases longevity of harvested parts thereof, and/or enhances nutrient content. In some embodiments, the benzoxaborole compounds or benzoxaborole compositions also display antimicrobial activity.

Abstract: A benzoxaborole formulation composition including a benzoxaborole, a non-ionic surfactant, or a non-ionic and ionic surfactant mixture, and a carrier is described herein. At least one of the non-ionic surfactant, the non-ionic and ionic surfactant mixture, and the carrier comprise a Lewis base or a N—H or O—H bond. The carrier is a solid or a liquid. Benzoxaborole compounds and methods of using the compounds and formulations of the compounds are described. For example, a method for reducing, preventing, ameliorating, or inhibiting an infestation by a pathogen by applying a compound or a formulation of a compound, wherein the pathogen is selected from insects, nematodes, bacteria, microbes, fungi, protozoa, viruses, and parasites, or any combinations thereof is described.

Abstract: The invention discloses a method for diagnosing recurrence and treating a triple negative breast cancer (TNBC) in a subject by use of multiple epidermal growth factor-like domains 11 (MEGF11) as a diagnostic and prognostic biomarker and a therapeutic target.

Abstract: The present invention relates to solid forms of a substituted benzoxaborole compound, specifically crystalline forms of a compound of formula I, compositions comprising crystalline forms of the compound of formula (I), and methods of their use.

Abstract: The present invention provides a voltage level shifter architecture applicable for positive and negative voltage shifting, in which a shielding circuit is configured to relax the voltage stress of the transistors in the input stage circuit, and a switching circuit is configured to avoid current leakage. In addition, designing the power domain(s) of the n-well P-type transistors in the voltage-level shifter makes the voltage-level shifter area-efficient and power-efficient or design-flexible and application-adaptive.

Abstract: The present invention relates to solid forms of a substituted benzoxaborole compound, specifically crystalline forms of a compound of formula I, compositions comprising crystalline forms of the compound of formula (I), and methods of their use.

Abstract: A method for controlling and adjusting a machining parameter of a processing machine detects and acquires information of workpieces during processing, and calculates an error compensation depending on the detected information and a mathematical model. The error compensation is compared with a first preset value and a determination made as to whether the error compensation is greater than a first preset value. The machining parameter is adjusted when the error compensation is not greater than the first preset value, the processing machine can be stopped if greater. An apparatus, and a non-transitory computer readable medium for controlling the machining parameter are also disclosed.